BenevolentAl Therapeutics Pipeline and Triage
Project 'Y' - a Benevolent tech-augmented programme
Novel target identified
in Target ID
No prior literature
association with
disease of interest
One main chemotype
reported in the
literature
Covered extensively by
>20 patents
Multiple closely-related
cores also claimed -
challenge to identify
novel chemical space
Close family members
with known safety risks
so selectivity important
Hit ID & Hit Expansion
completed in 7
months
Employed both Virtual
Screening and focused
Fragment Screening
approaches
Project now in late
Lead Optimisation
13 months, 380 compounds
Low nM potency
●
200 fold selectivity over all
family members
Low metabolic clearance in
microsomes and
hepatocytes (Eh <0.4)
Good aqueous solubility
(>200uM)
Clean in Ames, hERG and
Cyp inhibition assays.
Internal Company programme - target confidential, no prior literature detected by Benevolent Platform™
Lead Optimisation stats from internal Company experimental data.
Al
Benevolent 31View entire presentation